- May 6, 2023– IMU-856 is an Orally Available, Systemically Acting, Highly Selective and Potent Small Molecule Modulator of SIRT6 – – Targets…
- May 4, 2023– Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of…
- April 27, 2023– Thought-Leader in Multiple Sclerosis with Decades of Experience in Academic Medicine and the Pharmaceutical Industry – NEW YORK, April…
- April 26, 2023NEW YORK, April 26, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- April 5, 2023– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – –…
- March 2, 2023NEW YORK, March 2, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- February 23, 2023– Initial Results From Ongoing Part C of Phase 1 Clinical Trial of IMU-856 in Celiac Disease Expected Mid-2023 –…
- February 22, 2023– Long-Term Open-Label Treatment With Vidofludimus Calcium Was Associated With a Low Rate of Confirmed Disability Worsening (CDW) Over Time…
- February 16, 2023– Webcast to be Held at 8:00 am ET on February 23, 2023 – NEW YORK, February 16, 2023 – Immunic,…
- February 9, 2023– Conference Call and Webcast to be Held Today, February 9, 2023, at 11:00 am ET – NEW YORK, February…
